Pharmaceutical maker and biotechnology company Novartis is reporting positive topline results from a phase 3 trial of a drug to treat a rare kidney disease.
Read the full post on Becker's Hospital Review - Healthcare News
Novartis reports success in phase 3 trial of drug for rare kidney disease
